鼻咽癌小剂量顺铂增敏辅助放疗的临床研究

目的：探讨鼻咽癌放疗后程同步辅以小剂量顺铂增敏的近期疗效,并与常规治疗和后程加速超分割放射治疗进行比较。方法：选取98例Ⅱ～Ⅳ期鼻咽癌患者,随机分为常规治疗组（简称T_1组,32例）、后程加速超分割治疗组（简称T_2组,32例）和顺铂加后程加速超分割治疗组（简称T_3组,34例）,并对治疗效果进行比较。结果：T_1组鼻咽部肿瘤消除率为75.0%（24/32）,颈部淋巴结消除率为87.5%（28/32）;T_2组鼻咽部肿瘤消除率为87.5%（28/32）,颈部淋巴结消除率为84.4%（27/32）：T_3组鼻咽部肿瘤消除率为97.1%（33/34）,颈部淋巴结消除率为91.2%（31/34）。进行两两比较,均为P〈0.05,有统计学意义,疗效：T_3组〉T_2组〉T_1组。治疗副作用有增加（P〉0.05）,但无统计学意义。结论：小剂量顺铂加后程加速超分割治疗鼻咽癌,可以达到较常规治疗更好的近期治疗效果。

Treatment With Late Course Accelerated Fractionation（LCAF） Radiotherapy and Low Dose Cisplatin in Nasopharyngeal Carcinoma

Objective：To study the later therapeutic efficacy of nasopharyngeal carcinoma in late course accelerated fractionation（LCAF） radiotherapy and low dose cisplatin,at same time compare with conventional fractionation and LCAF.Methods：Ninety-eight cases with stageⅡ～Ⅳof nasopharyngeal carcinoma were randomly assigned to three groups：conventional fractionation（T_1）.LCAF（T_2）,LCAF and low dose cisplatin（T_3）.At the end of treatment,therapeutic efficacy was compared with each other.Results：The survey periods was 3 months.Comlete response rate（CR） for groups T1,T2 and T3 was 75.0%（24/32）,87.5%（28/32） and 97.1%（33/31）.respectively; the group treated with LCAF and cisplatin had highest effective later therapeutic efficacy than other groups. Lymph node of neck of group T3 got better control,although its side effects were more serious,but no significant difference was found among three group.Conclusion：Combined treatment of LCAF radiotherapy and low dose cisplatin has better later therapeutic efficacy on tumor control in patients with nasopharyngeal carcinoma